ESE. A. Shcheglov

E. A. Shcheglov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Shcheglov has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Joint osteoarthritis: Is there something we can do without a scalpel and a pill?

    by E. A. Shcheglov, N. N. Alontseva

    Osteoarthritis oflarge joints, including knee osteoarthritis, is one of the most common diseases. Pain is one of the main symptoms of knee osteoarthritis (KOA). Itleads to a decrease in quality oflife for patients. Despite undeniable advances in both surgical and medical treatments, this problem remains far from resolved. As a result of searching the PubMed, Web of Science, Scopus, Cochrane Library and eLIBRARY.RU electroniclibrary databases, 99 publications were selected from the period from 1999 to 2025, including data from randomized controlled trials,longitudinal and cohort studies, practical and clinical guidelines. This article focuses on non-pharmacological treatments for KOA, specifically the use of specialized braces, orthoses, and insoles. Current data on these devices effectiveness in osteoarthritis treatment are presented. The use of braces and orthoses helps relieve pressure on the knee joint, reduce pain, improve quality oflife, and accelerate rehabilitation after surgery. Comparative results of orthosis and brace use are analyzed. Wedge-shaped insoles should be an important element of treatment for patients with KOA. They can serve both as a preventative measure for the osteoarthritis development and as a treatment method for slowing the progression of existing disease. Furthermore, wedge-shaped insoles help improve the musculo-venous pump function and normalize venous outflow from thelimb, which is extremely important given the currently available data on the role of chronic venous disease in the development and progression of osteoarthritis. Therefore, biomechanical devices should be a mandatory component of the treatment of patients with knee osteoarthritis.

  • About the possibility of using a new biologically active supplement in the treatment of chronic venous diseases

    by A. B. Sannikov, E. V. Shaydakov, E. A. Shcheglov, A. M. Shevchenko, A. Zh. Meltsova, I. A. Klubkova

    Introduction . The use of various venotonic drugs is an integral part of the comprehensive treatment of patients with chronic venous diseases (CVD). Aim . To evaluate the clinical efficacy of a new domestic biologically active supplement (BAS) consisting of the flavonoid hesperidin methyl chalcone (HMC), troxerutin (HER) and ascorbic acid (VitC) in the complex treatment of patients with CVD of clinical classes C1–C3 (according to CEAP). Materials and methods . The open, comparative multicenter, prospective study included 281 patients with CVD (varicose veins) of clinical classes C1–C3 (according to CEAR). The first (studied) group of patients included 158 people who received Russian biologically active supplement (HMC + HER + VitC) for two months. The second (control) group consisted of 123 patients who did not receive biologically active supplement. In order to study the effectiveness of BAS sequentially during three patient visits, a statistical analysis of changes in quality of life according to the CIVIQ-2 questionnaire, pain intensity using a visual analog scale (VAS) and the dynamics of changes in malleolar volume (MV) on the target limb under study was performed. Results . The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement (HMC + HER +VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality of life of patients. The maximum effectiveness of Russian biologically active supplement (HMC + HER + VitC) is manifested after 2 months of use in standard dosages without any side effects. The main advantage of the new biologically active supplement is its complete solubility in water and, as a result, higher bioavailability. Conclusions . The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement supplement (HMC + HER + VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality oflife of patients.

  • Open Access

    The role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment

    by E. A. Shcheglov, N. N. Alontseva

    Chronic venous diseases of the lower extremities, including varicose veins, are one of the most common pathologies in modern society, affecting up to 73% of women and up to 56% of men. Despite significant advances in surgical treatment, the role of conservative therapy in the treatment of this disease does not diminish. The main group of drugs used in the conservative treatment of venous pathology are the so-called phlebotropic drugs, which are a fairly diverse group of medications of both natural and synthetic origin. One of the leading places among phlebotropic drugs is occupied by micronized purified flavonoid fraction, which is a venoactive drug consisting of diosmin 900 mg and flavonoids, in terms of hesperidin 100 mg. The effectiveness of micronized purified flavonoid fraction in relation to venous symptoms, including pain, heaviness, edema, trophic disorders and others has been demonstrated in many studies. When using MPFF, venous trophic ulcers healed faster and more frequently than in the control group without the drug. The drug was effective in patients who received invasive treatment for varicose veins, both sclerotherapy and open and endovascular interventions. The drug also proved itself in patients with various comorbid disorders, such as phlebogonarthrosis. There is a significant amount of data demonstrating the effectiveness of MPFF in pelvic varicose veins. Currently, in addition to the original drug, there are 4 generics on the market, to which, according to the current point of view, the effects proven in the study of the original drug cannot be transferred. However, the drug Detravenol in a comparative study demonstrated the same efficacy and safety profile as the original drug. This gives our patients the opportunity to choose between the original and the reproduced drug.


  • Open Access

    Discussion on the issue of primacy of the lower extremities varicosity and knee osteoarthritis

    by E. A. Shcheglov

    Дискуссия по вопросу первичности варикозной болезни нижних конечностей и остеоартроза коленных суставов

  • Open Access

    Neurologic complications of foam sclerotherapy

    by E. A. Shcheglov, A. V. Evmenсhikov, O. A. Kalinovskaya, A. S. Danilova, V. I. Maksimov, M. A. Popova

    The article is devoted to the description of a clinical case of neurological complications of foam sclerotherapy. The goal is to familiarize doctors with a fairly serious complication of the procedure, most often performed for cosmetic purposes. Stroke and transient ischemic attacks have been reported as “isolated cases” following sclerotherapy. Visual disturbances and complaints of headaches and migraines are much more common (0.1–1%). The main causes of these disorders are either gas embolism, which occurs immediately after the procedure, or paradoxical thromboembolism, which is recorded some time after sclerotherapy. The main cause of disorders is congenital heart disease, atrial or ventricular septal defect, however, total screening before the procedure is considered inappropriate. It is recommended to limit the volume of foam injected to 10 ml and carefully collect anamnesis. A history of heart disease with a right-to-left shunt is an absolute contraindication to the procedure. A clinical case is described with a 39-year-old patient who had previously unde rgone foam sclerotherapy sessions for cosmetic reasons. During the third session of sclerotherapy, the patient developed signs of acute cerebrovascular accident, which required hospitalization and treatment in the neurological department. Congenital heart disease has not been previously detected. Subsequently, with the treatment, all neurological disorders completely regressed. Conclusions. Doctors should be aware of the possibility of developing the serious complication described in the article, which, under unfavorable circumstances and lack of timely medical care, can lead to disability of the patient. If this complication develops, it is necessary to refer the patient to a neurologist as soon as possible to establish a diagnosis and begin therapy.

  • Open Access

    Chronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis

    by E. A. Shcheglov, N. N. Alontseva

    Introduction. Chronic vein diseases in general and varicose veins of the lower extremities in particular represent a serious medical and social problem.The aim was to study the influence of the therapy of venous outflow disorders on the treatment results of osteoarthritis of the knee joints in patients with varicose veins in combination with osteoarthritis of the knee joints.Materials and methods. The study included 105 patients with varicose veins combined with knee osteoarthritis who had previously received treatment for osteoarthritis of the knee joints but had not received or had received extremely irregular therapy for varicose veins. The follow-up period for the patients was 12 months. The patients underwent the first course of phlebotropic drugs for 2 months from the start of the study. Then this course was repeated twice at 3-month intervals. The standard phlebotropic drug was a micronized purified flavonoid fraction. Compression knitwear was recommended in all patients. Class 2 stockings or tights with an ankle pressure of 23–32 mmHg were used in the vast majority of cases. Treatment of osteoarthritis included the use of nonsteroidal anti-inflammatory drugs, disease-modifying agents (chondroitin sulfate, glucosamine sulfate), and physical therapy.Results. The VCSS scale reduced the degree of chronic venous insufficiency in the clinical group. At inclusion in the study, the average score in the clinical group was 7.1 ± 1.9, after 6 months the result was 6.1 ± 1.5, and after 12 months – 6.0 ± 1.2 points. In the control group, where patients did not receive therapy for varicose veins, there were no dynamics. The results of joint syndrome against the background of correction of venous outflow disturbances – decrease of Leken and WOMAC index values, decrease of pain syndrome according to the visual analogue scale. All this led to a decrease in the patients' need for taking analgesics.Conclusions. Out of 100 patients with joint pathology, 68 patients were diagnosed with varicose veins. These diseases aggravate each other, but we can assume that the venous pathology is primary. A vicious circle is set in motion – progression of osteoarthritis due to the disturbances of venous outflow, and varicosity due to the deterioration of muscular-venous pump functioning.


  • Open Access

    RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM

    by E. A. Shcheglov, N. N. Alontseva, P. S. Guliaeva

    The aimof this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis.Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gastroduodenoscopic procedure prior to the anticoagulant treatment. When erosive-ulcerative lesions were detected, the patients received antisecretory therapy with proton pump inhibitors along with anticoagulant therapy.Results: EGD did not show any only stomach pathology only in 10.7 percent of patients at the time of admission. A symptom-free pathology that became a diagnostic finding was identified in 53.1 percent of patients. Fiberoptic gastroduodenoscopy showed completed bleeding or bleeding that was stopped using endoscopic balloon tamponade with achievement of stable hemostasis in 12.9 patients. 59.1 percent of patients received anti-coagulant therapy with rivaroxaban (Xarelto®). In the presented series of patients with acute deep vein thrombosis, the use of rivopoxaban appeared a safe therapeutic option not only in patients with erosive-ulcerative lesions in the gastroduodenal system, but also in those with endoscopic signs of stopped bleeding (on the top of already administered antisecretory therapy with proton pump inhibitors).

  • Open Access

    Chronic Venous Insufficiency and Gonarthrosis

    by E. A Shcheglov, Щеглов Анатольевич Щеглов

    The rate of previously not diagnosed chronic insufficiency in patients with knee osteoarthrosis was determined. The effect of treatment measures directed to elimination of venous insufficiency was evaluated. It was shown that in 48.8% of patients chronic venous insufficiency was not diagnosed by orthopaedic surgeons. Observance of therapeutic regimen, use of elastic compression and phlebotropic drugs contributed to the elimination of gonarthrosis symptoms and improved the quality of life (by KOOS scale).